EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

The 400-mg dose cut Lp(a) by 93.9 percentage points compared with placebo from day 60-180 after the initial subcutaneous injection ... were "favorable," with injection site reactions in up ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

US-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I ...

Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

Acumen Pharmaceuticals Inc (ABOS) reports robust cash reserves and advances in Alzheimer's research, despite increased R&D expenses and competitive challenges.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q4 2024 Earnings Call Transcript March 27, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were ...

As a new animal habitat sprung up at Phoenix Zoo, two California condors watched closely. Then they learned who was moving in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...